FDA approves Neffy, a nasal spray for children's allergies

San Diego's ARS Pharmaceuticals has received FDA approval for Neffy, a 1 milligram epinephrine nasal spray for children aged 4 and older. This needle-free alternative aims to treat severe allergic reactions without the need for injections. Neffy is designed for children weighing between 33 and 66 pounds. It offers a user-friendly option that may encourage quicker treatment during allergic emergencies. The product is expected to be available in the U.S. by the end of May. The nasal spray is priced at about $25 for insured patients, while uninsured patients may pay around $200 for two doses. ARS Pharmaceuticals plans to develop a smaller dose for younger children and is working to expand commercial coverage for Neffy.